Alex Goldberg

Antares Pharma Inc. (NASDAQ:ATRS) and Geron Corporation (NASDAQ:GERN) Added to Equity Profile Report's NASDAQ Active Stock Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 10/07/2013 -- Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding Antares Pharma Inc. (NASDAQ:ATRS) and Geron Corporation (NASDAQ:GERN).

Antares Pharma Inc. (NASDAQ:ATRS) operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies, and topical gel-based medicines worldwide is currently down (-0.48%) on 1,132,884 shares traded. Antares Pharma Inc. (NASDAQ:ATRS) is currently down (-4.24%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Antares Pharma Inc. (NASDAQ:ATRS)

Geron Corporation (NASDAQ:GERN) a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies is currently up (+0.90%) on 745,127 shares traded. Geron Corporation (NASDAQ:GERN) is currently down (-20.25%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Geron Corporation (NASDAQ:GERN)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com